From 8322 patients for whom creatine kinase (CK; EC 2.7.3.2) isoenzyme analysis was ordered, we identified 136 patients with macro CK isoenzyme in their serum. There were 36 cases with type 1 (prevalence: 0.43%) and 100 cases with type 2 isoenzyme (prevalence: 1.20%). About three-fourths of the patients were ambulatory at the time of testing, and ~90% of the first 68 patients identified survived at least 1 year after macro CK was found in their serum. Age and gender did not differ significantly between the two groups. The serum total CK was significantly higher (P < 0.0005), and an increased CK-MB proportion (>0.05 of total CK) was also significantly more common (P < 0.0005) in patients with macro CK type 1 than in those with type 2. On average, macro CK type 2 accounted for ~25% and macro CK type 1 for ~10% of the serum total CK activity. Patients with macro CK type 1 most often had myositis, whereas those with macro CK type 2 most commonly had a malignancy. We conclude that the presence of macro CK isoenzymes has a low prognostic value for impending death, but may support the diagnosis of an autoimmune process (type 1) or malignant cell proliferation (type 2).
CITATION STYLE
Lee, K. N., Csako, G., Bernhardt, P., & Elin, R. J. (1994). Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clinical Chemistry, 40(7 I), 1278–1283. https://doi.org/10.1093/clinchem/40.7.1278
Mendeley helps you to discover research relevant for your work.